FORTRESS BIOTECH INC - FBIO 9 3/8 PERP (FBIOP) Stock Price, Forecast & Analysis
USA - NASDAQ:FBIOP - US34960Q2084
FBIOP Key Statistics, Chart & Performance
The current stock price of FBIOP is 6.8 USD. In the past month the price increased by 0.61%. In the past year, price increased by 33.33%.
FBIOP Latest News, Press Relases and Analysis
FBIOP Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.68 | 412.01B | ||
| AMGN | AMGEN INC | 15.38 | 181.04B | ||
| GILD | GILEAD SCIENCES INC | 15.07 | 153.12B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.01 | 111.32B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.15 | 72.26B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 887.73 | 59.35B | ||
| INSM | INSMED INC | N/A | 41.09B | ||
| NTRA | NATERA INC | N/A | 28.75B | ||
| BIIB | BIOGEN INC | 9.65 | 23.67B | ||
| INCY | INCYTE CORP | 16.86 | 21.14B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.49 | 20.88B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 35.13 | 14.56B |
Related stock screener links
About FBIOP
Company Profile
Fortress Biotech, Inc. engages in the manufacture and commercialization of novel pharmaceutical products and product candidates. The company is headquartered in Bay Harbor Islands, Florida and currently employs 101 full-time employees. The company went IPO on 2011-11-17. The firm has eight marketed prescription pharmaceutical products and over 20 programs in development, with its majority-owned and majority-controlled partners and subsidiaries and partners and subsidiaries it founded and in which it holds significant minority ownership positions. Its portfolio is being commercialized and developed for various therapeutic areas, including oncology, dermatology, and rare diseases. Its dermatology products include Emrosi, Qbrexza, Amzeeq, Zilxi, Exelderm, Targadox, and Luxamend. Its late-stage product candidates include CUTX-101 (copper histidinate injection for Menkes disease), Triplex (cytomegalovirus (CMV) vaccine), and CAEL-101 (monoclonal antibody for AL amyloidosis). Its early and mid-stage product candidates include Dotinurad (urate transporter (URAT1) inhibitor for gout), MB-101 (IL13Rα2 CAR T Cell Program for Glioblastoma), and others.
Company Info
FORTRESS BIOTECH INC - FBIO 9 3/8 PERP
1111 Kane Concourse, Suite 301
Bay Harbor Islands FLORIDA US
Employees: 101
Phone: 17816524500
FORTRESS BIOTECH INC - FBIO 9 3/8 PERP / FBIOP FAQ
Can you describe the business of FORTRESS BIOTECH INC - FBIO 9 3/8 PERP?
Fortress Biotech, Inc. engages in the manufacture and commercialization of novel pharmaceutical products and product candidates. The company is headquartered in Bay Harbor Islands, Florida and currently employs 101 full-time employees. The company went IPO on 2011-11-17. The firm has eight marketed prescription pharmaceutical products and over 20 programs in development, with its majority-owned and majority-controlled partners and subsidiaries and partners and subsidiaries it founded and in which it holds significant minority ownership positions. Its portfolio is being commercialized and developed for various therapeutic areas, including oncology, dermatology, and rare diseases. Its dermatology products include Emrosi, Qbrexza, Amzeeq, Zilxi, Exelderm, Targadox, and Luxamend. Its late-stage product candidates include CUTX-101 (copper histidinate injection for Menkes disease), Triplex (cytomegalovirus (CMV) vaccine), and CAEL-101 (monoclonal antibody for AL amyloidosis). Its early and mid-stage product candidates include Dotinurad (urate transporter (URAT1) inhibitor for gout), MB-101 (IL13Rα2 CAR T Cell Program for Glioblastoma), and others.
What is the stock price of FORTRESS BIOTECH INC - FBIO 9 3/8 PERP today?
The current stock price of FBIOP is 6.8 USD. The price increased by 1.49% in the last trading session.
Does FBIOP stock pay dividends?
FBIOP does not pay a dividend.
What is the ChartMill rating of FORTRESS BIOTECH INC - FBIO 9 3/8 PERP stock?
FBIOP has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What sector and industry does FORTRESS BIOTECH INC - FBIO 9 3/8 PERP belong to?
FORTRESS BIOTECH INC - FBIO 9 3/8 PERP (FBIOP) operates in the Health Care sector and the Biotechnology industry.
What is the Price/Earnings (PE) ratio of FORTRESS BIOTECH INC - FBIO 9 3/8 PERP (FBIOP)?
FORTRESS BIOTECH INC - FBIO 9 3/8 PERP (FBIOP) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.49).
When is the next dividend date for FORTRESS BIOTECH INC - FBIO 9 3/8 PERP (FBIOP)?
The next ex-dividend date for FORTRESS BIOTECH INC - FBIO 9 3/8 PERP (FBIOP) is June 14, 2024.
FBIOP Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to FBIOP. When comparing the yearly performance of all stocks, FBIOP turns out to be only a medium performer in the overall market: it outperformed 68.68% of all stocks.
FBIOP Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to FBIOP. FBIOP may be in some trouble as it scores bad on both profitability and health.
FBIOP Financial Highlights
Over the last trailing twelve months FBIOP reported a non-GAAP Earnings per Share(EPS) of -2.49. The EPS increased by 37.44% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -15.04% | ||
| ROE | -54.76% | ||
| Debt/Equity | 1.14 |
FBIOP Forecast & Estimates
8 analysts have analysed FBIOP and the average price target is 29.24 USD. This implies a price increase of 330.05% is expected in the next year compared to the current price of 6.8.
For the next year, analysts expect an EPS growth of 69.12% and a revenue growth 26.68% for FBIOP